S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
RATIONALE: Gathering information about how often osteonecrosis of the jaw occurs in patients receiving zoledronic acid for bone metastases may help doctors learn more about the disease and provide the best follow-up care. PURPOSE: This clinical trial is studying osteonecrosis of the jaw in patients with cancer who are receiving zoledronic acid for bone metastases.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Jul 5, 2019 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Observational
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- SWOG Cancer Research Network
- Interventions being studied
- Procedure: assessment of therapy complications
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- DISEASE CHARACTERISTICS:
- Participant must have bone metastasis from multiple myeloma, solid tumors, or other malignancy for which intravenous bisphosphonate has clinical indications in the treatment of metastatic bone disease
- Treatment with osteoclast inhibition is clinically indicated
- Must be planning to receive zoledronic acid\
- within the next 30 days NOTE: \*Osteoclast inhibition therapy will continue thereafter as clinically indicated.
- No prior diagnosis of osteonecrosis of the jaw
- Patients previously treated with osteoclast inhibition therapy are eligible, provided the following criteria apply:
- Prior osteoclast inhibition for low bone mass (osteoporosis or osteopenia):
- Patients may have previously received at most 3 doses of osteoclast-inhibiting therapy with denosumab, IV ibandronate, pamidronate, or zoledronic acid for low bone mass (osteopenia or osteoporosis) within 3 years prior to registration
- Prior oral bisphosphonate therapy at osteoporosis or osteopenia dosing at any time prior to registration is allowed
- Prior exposures to other medications used to treat low bone mass at osteoporosis or osteopenia dosing are permitted
- Prior osteoclast inhibition for metastatic bone disease (tumor involving bone):
- Patients may have previously received osteoclast-inhibiting therapy with denosumab, ibandronate (oral or IV cancer dosing), pamidronate, or zoledronic acid to treat metastatic bone disease within 180 days prior to registration
- Patients receiving these regimens for metastatic bone disease prior to 180 days before registration are not eligible
- Prior osteoclast-inhibiting therapy at higher dosing than outlined above at any time prior to registration is not allowed PATIENT CHARACTERISTICS:
- Zubrod performance status 0-3
- Patients who may be acutely ill from spinal cord compromise, hypercalcemia of malignancy, or other process may be study candidates once the acute condition has been addressed and performance status improves to 0-3
- Not pregnant or nursing
- Negative pregnancy test
- Willing and physically able to comply with study procedures and assessments
- Willing to provide information on personal history, including tobacco and alcohol use, and pain assessment
- Willing to provide access to prior and future dental information
- No other prior malignancy except for any of the following:
- Adequately treated basal cell carcinoma or squamous cell carcinoma of the skin
- In situ cervical cancer
- Adequately treated stage I or II cancer for which the patient is currently in complete remission
- Any other cancer for which the patient has been disease-free for 5 years PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No history of radiation to the maxillofacial area administered for therapeutic intent in the treatment of cancer
- Concurrent participation in other therapeutic and non-therapeutic clinical trials allowed
- The sum of prior IV bisphosphonate doses must not be greater than 10
- The sum of prior denosumab doses must not be greater than 8
- The total of both IV bisphosphonate and denosumab used for any indication must not be greater than 12 doses
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Regional Medical CenterAnniston, Alabama
- Providence Cancer Center at Providence HospitalMobile, Alabama
- Providence Cancer CenterAnchorage, Alaska
- Fairbanks Cancer Treatment Center at Fairbanks Memorial HospitalFairbanks, Alaska
- NEA Medical Clinic - East MatthewsJonesboro, Arkansas
- Arkansas Cancer Research Center at University of Arkansas for Medical SciencesLittle Rock, Arkansas
- East Bay Radiation Oncology CenterCastro Valley, California
- Valley Medical Oncology Consultants - Castro ValleyCastro Valley, California
- Cancer Care Center at John Muir Health - Concord CampusConcord, California
- City of Hope Comprehensive Cancer CenterDuarte, California
- North Bay Cancer CenterFairfield, California
- Valley Medical OncologyFremont, California
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 5, 2019. Always confirm current availability with the study team.